Analysis of circulating cell-free DNA identifies multi-clonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors

Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination (HRR) such as BRCA2. HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib. In ovarian or breast cancers, olaparib resistance ha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Quigley, David, Alumkal, Joshi J., Wyatt, Alexander W., Kothari, Vishal, Foye, Adam, Lloyd, Paul, Aggarwal, Rahul, Kim, Won, Lu, Eric, Schwartzman, Jacob, Beja, Kevin, Annala, Matti, Das, Rajdeep, Diolaiti, Morgan, Pritchard, Colin, Thomas, George, Tomlins, Scott, Knudsen, Karen, Lord, Christopher J, Ryan, Charles, Youngren, Jack, Beer, Tomasz M., Ashworth, Alan, Small, Eric J., Feng, Felix Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581695/
https://ncbi.nlm.nih.gov/pubmed/28450426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0146
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados